THRIVE-132: Therapy for Reduction in VOC Readmissions with Inclacumab

The THRIVE-132 study is determining the safety and efficacy of a single dose of inclacumab, an investigational therapy, as a possible treatment to prevent readmission to the hospital for a vaso-occlusive crises (VOCs) in individuals with sickle cell disease.

Locations

6 United States sites

3 Turkey sites

2 Lebanon sites

1 Italy site

1 Kenya site

1 Omanc site

Age

> 12 Years

Genotypes

All types of SCD

Phase

3

LEARN MORE
Hibiscus Study: An oral investigational medication for SCD

The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD.

Locations

1 United States site

1 Europe site

1 Canada site

Age

12 - 65 Years

Genotypes

All types of SCD

Phase

2/3

LEARN MORE
THRIVE-131: A study to potentially reduce VOCs in sickle cell

The THRIVE-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.

Locations

14 USA sites

4 Kenya sites

3 France sites

3 Italy sites

3 Turkey sites

2 Lebanon sites

1 Brazil site

1 Germany site

1 Saudi Arabia site

1 Oman site

1 Tanzania site

1 United Kingdom site

Age

> 12 Years

Genotypes

SCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia

Phase

3

LEARN MORE
CaRISMA Study: An alternative way to manage sickle cell disease

To identify treatments that do not rely only on opioids or other medications.

Locations

1 United States site

Age

> 18 Years

Genotypes

All types of SCD

Phase

N/A

LEARN MORE